Aska Pharmaceutical Holdings Co., Ltd. (4886) Press Release
Notice Regarding Results of the 5th Ordinary General Meeting of Shareholders
Earlier from Aska Pharmaceutical
- ASKA Pharmaceutical: May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area
- ASKA Pharmaceutical: April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries
- ASKA Pharmaceutical: March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication
- ASKA Pharmaceutical: July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)